サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1378888

肺炎球菌ワクチン市場レポート：ワクチンタイプ、製品タイプ、流通チャネル、エンドユーザー、地域別、2023-2028年

Pneumococcal Vaccine Market Report by Vaccine Type, Product Type, Distribution Channel (Distribution Partner Companies, Non-Governmental Organizations, Government Authorities), End User, and Region 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 146 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
肺炎球菌ワクチン市場レポート：ワクチンタイプ、製品タイプ、流通チャネル、エンドユーザー、地域別、2023-2028年
出版日: 2023年11月02日
発行: IMARC
ページ情報: 英文 146 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

肺炎球菌ワクチンの世界市場規模は2022年に89億米ドルに達しました。今後、IMARCグループは、2022年から2028年にかけて5.4%の成長率（CAGR）を示し、2028年までに122億米ドルに達すると予測しています。

肺炎球菌感染症は肺炎球菌によって引き起こされ、肺（肺炎）や血液（菌血症）、脳や脊髄の内壁（髄膜炎）に深刻な感染を引き起こす可能性があります。ワクチンは、免疫系を刺激し、重篤な感染症の原因となる細菌株から守ることで、小児と成人の両方を守るのに役立ちます。これらのワクチンは感染の拡大を防ぎ、致死率を下げ、入院の必要性をなくすため、世界中で広く使用されています。

世界保健機関（WHO）によると、2～5歳未満の小児は肺炎球菌感染症を発症するリスクが高いです。このことは、出生率の上昇や子供の健康に対する親の関心の高まりと相まって、市場の成長を後押しする主な要因のひとつとなっています。さらに、老年人口の増加が市場の成長に寄与しています。これは、高齢者に深刻な合併症を引き起こす可能性のある病気の伝染性にも起因しています。さらに、喫煙者や慢性的な健康状態にある人の数が増加していることも、市場の成長にプラスの影響を与えています。さらに、多くの国の行政機関が乳幼児の定期予防接種に肺炎球菌結合型ワクチン（PCV）を導入していることも、市場成長を促進すると予想されます。

本レポートで扱う主な質問

  • 2022年の世界の肺炎球菌ワクチン市場規模は？
  • 2023-2028年の世界の肺炎球菌ワクチン市場の予想成長率は？
  • COVID-19が世界の肺炎球菌ワクチン市場に与えた影響は？
  • 世界の肺炎球菌ワクチン市場を牽引する主な要因は？
  • ワクチンタイプに基づく世界の肺炎球菌ワクチン市場の内訳は？
  • 製品タイプに基づく肺炎球菌ワクチンの世界市場内訳は？
  • 世界の肺炎球菌ワクチン市場の流通チャネル別の区分は？
  • 肺炎球菌ワクチンの世界市場における主要地域は？
  • 肺炎球菌ワクチンの世界市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 肺炎球菌ワクチンの世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：ワクチンタイプ別

  • 肺炎球菌結合型ワクチン
    • 市場動向
    • 市場予測
  • 肺炎球菌多糖体ワクチン
    • 市場動向
    • 市場予測

第7章 市場内訳：製品タイプ別

  • プレブナール13
    • 市場動向
    • 市場予測
  • シンフロリックス
    • 市場動向
    • 市場予測
  • ニューモバックス23
    • 市場動向
    • 市場予測

第8章 市場内訳：流通チャネル別

  • 流通パートナー企業
    • 市場動向
    • 市場予測
  • 非政府組織（NGO）
    • 市場動向
    • 市場予測
  • 政府機関
    • 市場動向
    • 市場予測

第9章 市場内訳：エンドユーザー別

  • 小児
    • 市場動向
    • 市場予測
  • 成人
    • 市場動向
    • 市場予測

第10章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Astellas Pharma Inc.
    • GlaxoSmithKline Plc.
    • Merck & Co. Inc.
    • Panacea Biotec Ltd.
    • Pfizer Inc.
    • Sanofi S.A.
    • Serum Institute of India Pvt Ltd.
    • Walvax Biotechnology Co. Ltd.
図表

List of Figures

  • Figure 1: Global: Pneumococcal Vaccine Market: Major Drivers and Challenges
  • Figure 2: Global: Pneumococcal Vaccine Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Pneumococcal Vaccine Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Pneumococcal Vaccine Market: Breakup by Vaccine Type (in %), 2022
  • Figure 5: Global: Pneumococcal Vaccine Market: Breakup by Product Type (in %), 2022
  • Figure 6: Global: Pneumococcal Vaccine Market: Breakup by Distribution Channel (in %), 2022
  • Figure 7: Global: Pneumococcal Vaccine Market: Breakup by End User (in %), 2022
  • Figure 8: Global: Pneumococcal Vaccine Market: Breakup by Region (in %), 2022
  • Figure 9: Global: Pneumococcal Vaccine (Pneumococcal Conjugate Vaccine) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Pneumococcal Vaccine (Pneumococcal Conjugate Vaccine) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Pneumococcal Vaccine (Pneumococcal Polysaccharide Vaccine) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Pneumococcal Vaccine (Pneumococcal Polysaccharide Vaccine) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Pneumococcal Vaccine (Prevnar 13) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Pneumococcal Vaccine (Prevnar 13) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Pneumococcal Vaccine (Synflorix) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Pneumococcal Vaccine (Synflorix) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Pneumococcal Vaccine (Pneumovax 23) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Pneumococcal Vaccine (Pneumovax 23) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Pneumococcal Vaccine (Distribution Partner Companies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Pneumococcal Vaccine (Distribution Partner Companies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Pneumococcal Vaccine (Non-Governmental Organizations-NGO) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Pneumococcal Vaccine (Non-Governmental Organizations-NGO) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Pneumococcal Vaccine (Government Authorities) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Pneumococcal Vaccine (Government Authorities) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: Global: Pneumococcal Vaccine (Pediatrics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: Global: Pneumococcal Vaccine (Pediatrics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: Global: Pneumococcal Vaccine (Adults) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: Global: Pneumococcal Vaccine (Adults) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: North America: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: North America: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: United States: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: United States: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: Canada: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: Canada: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: Asia-Pacific: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: Asia-Pacific: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: China: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: China: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: Japan: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: Japan: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: India: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: India: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: South Korea: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: South Korea: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: Australia: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: Australia: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: Indonesia: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: Indonesia: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: Others: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: Others: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: Europe: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: Europe: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: Germany: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: Germany: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: France: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: France: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: United Kingdom: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: United Kingdom: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Italy: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Italy: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: Spain: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: Spain: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Russia: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Russia: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: Others: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: Others: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: Latin America: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: Latin America: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: Brazil: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: Brazil: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Mexico: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: Mexico: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Others: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 74: Others: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Middle East and Africa: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 76: Middle East and Africa: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Middle East and Africa: Pneumococcal Vaccine Market: Breakup by Country (in %), 2022
  • Figure 78: Global: Pneumococcal Vaccine Industry: SWOT Analysis
  • Figure 79: Global: Pneumococcal Vaccine Industry: Value Chain Analysis
  • Figure 80: Global: Pneumococcal Vaccine Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pneumococcal Vaccine Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Pneumococcal Vaccine Market Forecast: Breakup by Vaccine Type (in Million US$), 2023-2028
  • Table 3: Global: Pneumococcal Vaccine Market Forecast: Breakup by Product Type (in Million US$), 2023-2028
  • Table 4: Global: Pneumococcal Vaccine Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 5: Global: Pneumococcal Vaccine Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 6: Global: Pneumococcal Vaccine Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 7: Global: Pneumococcal Vaccine Market: Competitive Structure
  • Table 8: Global: Pneumococcal Vaccine Market: Key Players
目次
Product Code: SR112023A3133

Abstract

The global pneumococcal vaccine market size reached US$ 8.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 12.2 Billion by 2028, exhibiting a growth rate (CAGR) of 5.4% during 2022-2028.

Pneumococcal disease is caused by Streptococcus pneumoniae bacterium that can lead to severe infection of the lungs (pneumonia) and blood (bacteremia) or the lining of the brain and spinal cord (meningitis). The vaccines help protect both children and adults by stimulating the immune system and protecting against the bacterial strains responsible for severe infections. As these vaccines help prevent infection from spreading, reduce fatality rate and eliminate the need for hospitalization, they are widely being used across the globe.

According to the World Health Organization (WHO), children under 2-5 years of age are at a high risk of developing pneumococcal disease. This, in confluence with the escalating number of birth rates and the growing concerns among parents about the health of their children, represents one of the major factors bolstering the market growth. Additionally, the increasing geriatric population is contributing to the market growth. This can also be accredited to the contagiousness of the disease, which can cause severe complications in older adults. Furthermore, the rising number of smokers and individuals living with chronic health conditions is positively influencing the market growth. Moreover, the introduction of the Pneumococcal Conjugate Vaccine (PCV) in infant routine immunization by governing agencies of numerous countries is anticipated to propel the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global pneumococcal vaccine market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on vaccine type, product type, distribution channel and end user.

Breakup by Vaccine Type:

Pneumococcal Conjugate Vaccine

Pneumococcal Polysaccharide Vaccine

Breakup by Product Type:

Prevnar 13

Synflorix

Pneumovax 23

Breakup by Distribution Channel:

Distribution Partner Companies

Non-Governmental Organizations (NGO)

Government Authorities

Breakup by End User:

Pediatrics

Adults

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., GlaxoSmithKline Plc., Merck & Co. Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt Ltd and Walvax Biotechnology Co. Ltd.

Key Questions Answered in This Report

  • 1. What was the size of the global pneumococcal vaccine market in 2022?
  • 2. What is the expected growth rate of the global pneumococcal vaccine market during 2023-2028?
  • 3. What has been the impact of COVID-19 on the global pneumococcal vaccine market?
  • 4. What are the key factors driving the global pneumococcal vaccine market?
  • 5. What is the breakup of the global pneumococcal vaccine market based on the vaccine type?
  • 6. What is the breakup of the global pneumococcal vaccine market based on the product type?
  • 7. What is the breakup of the global pneumococcal vaccine market based on the distribution channel?
  • 8. What are the key regions in the global pneumococcal vaccine market?
  • 9. Who are the key players/companies in the global pneumococcal vaccine market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pneumococcal Vaccine Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Pneumococcal Conjugate Vaccine
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Pneumococcal Polysaccharide Vaccine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product Type

  • 7.1 Prevnar 13
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Synflorix
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Pneumovax 23
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Distribution Partner Companies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Non-Governmental Organizations (NGO)
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Government Authorities
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pediatrics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Adults
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Astellas Pharma Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 GlaxoSmithKline Plc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Merck & Co. Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Panacea Biotec Ltd.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Pfizer Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Sanofi S.A.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Serum Institute of India Pvt Ltd.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 Walvax Biotechnology Co. Ltd.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials